PT1a melanoma treatment: what to know

PT1a identifies a thin primary melanoma without ulceration. Because the diagnosis is based on tissue, the first biopsy may be followed by a wider excision to remove a margin of surrounding skin. The amount of tissue and the closure method depend on the lesion's site, size and the initial procedure. The final specimen is checked to confirm the margins and refine staging. A sentinel lymph node biopsy is considered selectively rather than assumed from the PT1a label alone.

Ask the surgeon what procedure is proposed, where the scar will be, how to care for the wound and when activity can resume. Keep the wound clean and follow the dressing instructions you receive. Do not apply unapproved products to a healing incision. Once your clinician says it is healed, protect the scar from strong sun. Keep a record of the pathology result and attend follow-up visits. Immunotherapy or other systemic treatment is not routine for every PT1a case; it depends on additional findings and specialist assessment.

After surgery, seek prompt advice for spreading redness, increasing warmth or pain, wound separation, persistent bleeding, pus or fever. Outside the recovery period, report a new changing mole, a spot that bleeds or does not heal, a lump near the scar or swelling in a nearby lymph-node area. Sudden neurological symptoms require urgent assessment.

Ask whether you need a wider excision, what the final margins show, whether sentinel node assessment is appropriate, and how often your skin should be examined. Ask how to recognise wound problems and which service to contact after hours.